[Inherited bone marrow failure syndromes]

Area of Science:

• Hematology
• Genetics
• Molecular Biology

Background:

• Diamond-Blackfan anemia (DBA) is an inherited bone marrow failure syndrome characterized by reduced reticulocytes and erythroid precursors.
• DBA is primarily caused by heterozygous mutations in ribosomal protein genes, leading to ribosome dysfunction.
• Impaired erythropoiesis in DBA involves p53 activation, translation defects, inflammation, and heme synthesis imbalance.

Purpose of the Study:

• To summarize the pathophysiology of Diamond-Blackfan anemia.
• To review current treatment strategies and their limitations.
• To highlight recent advances in gene therapy for DBA.

Main Methods:

• Literature review of DBA pathophysiology, clinical features, and treatment outcomes.
• Analysis of studies on ribosomal protein gene mutations and their impact on erythropoiesis.
• Evaluation of emerging gene therapy approaches for DBA.

Main Results:

• DBA is linked to ribosome dysfunction and impaired red blood cell production.
• Steroid therapy is a primary treatment, but many patients develop resistance.
• Hematopoietic cell transplantation offers a curative option, and gene therapy shows promise.

Conclusions:

• DBA pathogenesis involves complex molecular pathways affecting erythropoiesis.
• Current treatments have limitations, necessitating alternative therapeutic strategies.
• Lentiviral vector-mediated gene therapy presents a potential new avenue for treating DBA, particularly RPS19 deficiency.